Page 48 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

vascular risk factors; larger treatment differences between rivastigmine and placebo were found for
patients with vascular risk factors compared to patients without vascular risk factors.

No study compared outcomes among subgroups of patients taking a ChEI or memantine concurrently
with another drug to patients not concurrently taking the same medication.

Table 7: Summary of trials assessing subgroups
Author, Year N Study Results Quality
design Rating
Age
Schneider et al., 1998 35 2,126 Pooled Better cognitive scores (ADAS-cog) for RIV in Fair
Analysis patients older than 75 years
Race
Schneider et al., 1998 35 2,126 Pooled No differences in response to RIV between Fair
Analysis black and white patients
Sex
35
Schneider et al., 1998 2,126 Pooled No differences in response to RIV between male Fair
Analysis and female patients
Comorbid Vascular Dementia
38
AD2000 565 RCT Results not stratified; general efficacy of DON Good
supported in this mixed population
90
Erkinjuntti et al., 2002 592 RCT No comparison of patients with comorbid Fair
vascular disease to population with only AD;
general evidence of GAL efficacy in population
with comorbid vascular disease
91
Kumar et al., 2000 699 RCT RIV better than placebo for patients with and Fair
subgroup without vascular risk factors; larger differences
for patients with vascular risk factors

Alzheimer's Drugs Page 48 of 205